Cargando…
Tristetraprolin is a novel regulator of BDNF
Brain-derived neurotrophic factor (BDNF) regulates multiple biological processes ranging from central nervous system development and function to neuroinflammation and myogenic differentiation and repair. While coordination of BDNF levels is central in determining the biological outcome, mechanisms i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164675/ https://www.ncbi.nlm.nih.gov/pubmed/25279294 http://dx.doi.org/10.1186/2193-1801-3-502 |
_version_ | 1782334985676521472 |
---|---|
author | Kumar, Anmol Varendi, Kärt Peränen, Johan Andressoo, Jaan-Olle |
author_facet | Kumar, Anmol Varendi, Kärt Peränen, Johan Andressoo, Jaan-Olle |
author_sort | Kumar, Anmol |
collection | PubMed |
description | Brain-derived neurotrophic factor (BDNF) regulates multiple biological processes ranging from central nervous system development and function to neuroinflammation and myogenic differentiation and repair. While coordination of BDNF levels is central in determining the biological outcome, mechanisms involved in controlling BDNF levels are not fully understood. Here we find that both short (BDNF-S) and long (BDNF-L) BDNF 3’UTR isoforms contain conserved adenylate- and uridylate rich elements (AREs) that may serve as binding sites for RNA-binding proteins (ARE-BPs). We demonstrate that ARE-BPs tristetraprolin (TTP) and its family members butyrate response factor 1 (BRF1) and 2 (BRF2) negatively regulate expression from both BDNF-S and BDNF-L containing transcripts in several cell-lines and that interaction between TTP and AU-rich region in proximal 5’ end of BDNF 3’UTR is direct. In line with the above, endogenous BDNF mRNA co-immunoprecipitates with endogenous TTP in differentiated mouse myoblast C2C12 cells and TTP overexpression destabilizes BDNF-S containing transcript. Finally, RNAi-mediated knock-down of TTP increases the levels of endogenous BDNF protein in C2C12 cells. Our findings uncover TTP as a novel regulator of BDNF assisting future studies in different physiological and pathological contexts. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2193-1801-3-502) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4164675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-41646752014-10-02 Tristetraprolin is a novel regulator of BDNF Kumar, Anmol Varendi, Kärt Peränen, Johan Andressoo, Jaan-Olle Springerplus Research Brain-derived neurotrophic factor (BDNF) regulates multiple biological processes ranging from central nervous system development and function to neuroinflammation and myogenic differentiation and repair. While coordination of BDNF levels is central in determining the biological outcome, mechanisms involved in controlling BDNF levels are not fully understood. Here we find that both short (BDNF-S) and long (BDNF-L) BDNF 3’UTR isoforms contain conserved adenylate- and uridylate rich elements (AREs) that may serve as binding sites for RNA-binding proteins (ARE-BPs). We demonstrate that ARE-BPs tristetraprolin (TTP) and its family members butyrate response factor 1 (BRF1) and 2 (BRF2) negatively regulate expression from both BDNF-S and BDNF-L containing transcripts in several cell-lines and that interaction between TTP and AU-rich region in proximal 5’ end of BDNF 3’UTR is direct. In line with the above, endogenous BDNF mRNA co-immunoprecipitates with endogenous TTP in differentiated mouse myoblast C2C12 cells and TTP overexpression destabilizes BDNF-S containing transcript. Finally, RNAi-mediated knock-down of TTP increases the levels of endogenous BDNF protein in C2C12 cells. Our findings uncover TTP as a novel regulator of BDNF assisting future studies in different physiological and pathological contexts. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2193-1801-3-502) contains supplementary material, which is available to authorized users. Springer International Publishing 2014-09-06 /pmc/articles/PMC4164675/ /pubmed/25279294 http://dx.doi.org/10.1186/2193-1801-3-502 Text en © Kumar et al.; licensee Springer. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Research Kumar, Anmol Varendi, Kärt Peränen, Johan Andressoo, Jaan-Olle Tristetraprolin is a novel regulator of BDNF |
title | Tristetraprolin is a novel regulator of BDNF |
title_full | Tristetraprolin is a novel regulator of BDNF |
title_fullStr | Tristetraprolin is a novel regulator of BDNF |
title_full_unstemmed | Tristetraprolin is a novel regulator of BDNF |
title_short | Tristetraprolin is a novel regulator of BDNF |
title_sort | tristetraprolin is a novel regulator of bdnf |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164675/ https://www.ncbi.nlm.nih.gov/pubmed/25279294 http://dx.doi.org/10.1186/2193-1801-3-502 |
work_keys_str_mv | AT kumaranmol tristetraprolinisanovelregulatorofbdnf AT varendikart tristetraprolinisanovelregulatorofbdnf AT peranenjohan tristetraprolinisanovelregulatorofbdnf AT andressoojaanolle tristetraprolinisanovelregulatorofbdnf |